As of close of business last night, Elevation Oncology Inc’s stock clocked out at $2.90, up 13.28% from its previous closing price of $2.56. In other words, the price has increased by $+0.3400 from its previous closing price. On the day, 655496 shares were traded.
Ratios:
To gain a deeper understanding of ELEV’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.99 and its Current Ratio is at 12.99. In the meantime, Its Debt-to-Equity ratio is 0.48 whereas as Long-Term Debt/Eq ratio is at 0.48.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, SVB Securities on May 30, 2023, Upgraded its rating to Outperform and sets its target price to $8 from $5 previously.
On December 23, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $12.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELEV now has a Market Capitalization of 108.58M and an Enterprise Value of 43.74M.
Stock Price History:
Over the past 52 weeks, ELEV has reached a high of $5.89, while it has fallen to a 52-week low of $0.36. The 50-Day Moving Average of the stock is 1.9616, while the 200-Day Moving Average is calculated to be 1.4586.
Shares Statistics:
It appears that ELEV traded 2.70M shares on average per day over the past three months and 633.15k shares per day over the past ten days. A total of 42.41M shares are outstanding, with a floating share count of 34.72M. Insiders hold about 18.15% of the company’s shares, while institutions hold 76.02% stake in the company. Shares short for ELEV as of Jan 31, 2024 were 3.52M with a Short Ratio of 1.30, compared to 803.68k on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.31% and a Short% of Float of 9.39%.
Earnings Estimates
As of right now, 4 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.23 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.29, while EPS last year was -$0.82. The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.27 and low estimates of -$0.32.
Analysts are recommending an EPS of between -$1.43 and -$1.47 for the fiscal current year, implying an average EPS of -$1.45. EPS for the following year is -$1.23, with 4 analysts recommending between -$1.17 and -$1.35.
